macological studies indicated that the bound drugs labeled the peripheral benzodiazepine binding site. Binding to the peripheral benzodiazepine site was confined primarily to malignant cells with little binding to adjacent normal brain tissue or to necrotic tissue. Tumor cell binding was completely inhibited by preadministration of the peripheral benzodiazepine blocking agent PK 11195 at 5 mg/kg. The centrally selective benzodiazepine ligand clonazepam had no effect on PK 11195 binding to the tumor cells. When binding to other tumor cell lines grown in nude mice and nude athymic rats was evaluated, little or no peripheral benzodiazepine binding was detected on human pheochromocytoma (RN1) and neuroblastoma (SK-N-MC, SK-N-SH) tumor cells, respectively. However, high densities of peripheral benzodiazepine binding sites were observed on tumors derived from a human glioma cell line (ATCC HITB 14, U-87 MG). The presence of high concentrations of specific peripheral benzodiazepine receptors on glial tumors suggests that human primary central nervous system tumors could be imaged and diagnosed using peripheral benzodiazepine ligands labeled with positron-or y-emitting isotopes, Primary tumors of the central nervous system account for 1.2% of all autopsied deaths (1) (2) (3) . Each year in the United States 17,000 new cases of primary intracranial neoplasm are diagnosed to give an annual rate of 8.2 persons with newly diagnosed brain tumors per 100,000 population. Gliomas are the most common type of primary central nervous system tumor and account for about one-half of confirmed primary intracranial neoplasms (1) (2) (3) . The current methods for imaging central nervous system tumors depend either on agents that image the disruption of the blood-brain barrier by the tumor or on agents that image edema and density changes within the tumor and surrounding brain tissue (4) (5) (6) (7) (8) . The current methods, however, cannot distinguish between healthy brain and brain infiltrated with tumor cells. Furthermore, the methods rarely show changes that are specific to the tissue of tumor origin and do not measure tumor viability.
A vigorous interest in imaging and delivering radionuclides and antineoplastic agents to gliomas has emerged from the development of hybridoma and monoclonal antibody technology (9) (10) (11) (12) . Xenographs using 131I-labeled anti-glioma monoclonal antibodies have successfully imaged subcutaneous gliomas in athymic mice and intracranial gliomas in athymic rats (9) (10) (11) (12) . These new technologies are unlikely to replace computerized tomography or magnetic resonance imaging for examining brain tumors but are preparing the ground for innovative forms of tumor detection and therapy. We report here the successful imaging of a central nervous system glioma using in vivo ligands for the peripheral benzodiazepine binding site.
Two classes of benzodiazepine binding sites have been identified in mammalian tissues. One class of sites is located on neurons and represents the sites at which benzodiazepine ligands are thought to exert their antianxiety, anticonvulsant, and muscle relaxant effects (13) (14) (15) . High-affinity ligands for the second class of benzodiazepine binding sites (the "peripheral" binding site) have been shown to bind to astrocytes and rodent glial tumor lines in homogenate studies but bind very little to normal brain (16) (17) (18) (19) (20) Additional animals were given 3H-labeled PK 11195 (125 ,Ci) i.v. with no pretreatment. In all animals, arterial blood samples were withdrawn at 2-min intervals up to 10 min. Ten minutes after the radioligand injection, animals were decapitated. Their brains were then rapidly removed, frozen in dry ice, and mounted on tissue pedestals. Twenty-micrometer sections were cut on a cryotome, mounted on gelatin-coated glass slides, and dried at 600C. Sections of brain were also solubilized, and the radioactivity was extracted and analyzed for metabolites by TLC.
In parallel with the in vivo studies, a series of mice and rats were inoculated intracerebrally with C6 glioma cells (Wistar rats), human gliom4 (U-87 MG) cells (nude athymic rats), and human neuroblastoma cells (nude athymic mice). After 2-6 weeks, the rodents were decapitated, and the brains were removed and evaluated for in vitro benzodiazepine binding (24, 25 Sections from both the in vivo and in vitro experiments were then mounted in x-ray cassettes along with appropriate standards, apposed to Ultrofilm 3H (LKB) and exposed for 2-4 weeks. Resultant autoradiograms were analyzed as described (24) (25) (26) [3H]Flunitrazepam binding to peripheral sites on brain sections from rats with C6 gliomas indicated a high density of these sites on the C6 glioma cells (Fig. 1) . Binding to the central sites, however, completely avoided areas of tumor cell growth. Binding to the tumor cells was affected only by those drugs known to be active at the peripheral site-i. Sections assayed for peripheral and central benzodiazepine binding were counterstained with cresyl violet. Direct comparisons could be made between areas with intact tumor cells and those in which the tumor had undergone necrotic changes. Binding was present in all nonnecrotic areas. In areas where there was necrosis, binding was absent or greatly reduced.
Brains from nude athymic rats and nude athymic mice with tumors derived from human U-87 MG glioma, neuroblastoma, and pheochromocytoma cell lines were examined for [3H]flunitrazepam binding (Table 1) . Peripheral benzodiazepine binding sites were present in high density on U-87 MG glioma tumors, but were very low on the pheochromocytoma tumors, and absent on the neuroblastoma tumors. No central benzodiazepine binding sites were detectable on U-87 MG glioma or neuroblastoma tumors and were minimally detectable on pheochromocytoma tumors. The density of peripheral binding sites on U-87 MG gliomas (Fig. 2) was about half that observed in kidney and C6 gliomas.
In gliomas pretreated with clonazepam at 5 mg/kg demonstrated striking images of the tumors on a background of minimal binding to normal brain (Fig. 3 A and B (Fig. 3 C and   D) .
The tumors were also imaged after in vivo intravenous administration of 3H-labeled PK 11195 (Fig. 4 A and B) . 3H-labeled PK 11195 binding correlated with the presence of clusters of tumor cells (Fig. 4 C and D (20, 33) , and mouse melanoma lines (34) . In some of the lines, peripheral benzodiazepine ligands alter tumor cell growth and differentiation (32) (33) (34) . Whether the binding sites on the C6 glioma and U-87 MG glioma lines control aspects of growth and differentiations has yet to be determined. The presence of receptors for neurotransmitters and neuromodulators on astrocytes and certain cultured tumor cell lines has been observed. These receptors include yaminobutyric acid, ,-adrenergic, muscarinic cholinergic, and other receptors (35) (36) (37) (38) (39) (40) (41) (42) . Most of these receptors, however, are also present on nerve cells. Thus, ligands for imaging these receptors would be unlikely to serve as agents that could easily distinguish normal from abnormal brain. Peripheral benzodiazepine ligands on the other hand, bind very poorly to normal rat and human brain with the highest concentration of sites (Bmax) approaching 300 fmol/mg of protein (29) . These same ligands label C6 and U-87 MG gliomas very densely. The presence of these binding sites on human glioma tumor cell lines suggests several areas for future research. These ligands could be labeled with positronor Ry-emitting isotopes and used for imaging brain tumors in man by positron or single-photon emission tomography. The clinical advantages of determining ligand binding in vivo in man is that binding could define regions of viable tumor for biopsy and for surgery, help the clinician determine the location of the tumor borders and the presence infiltrating cells, and aid in assessing response to therapy. The reaction of highly specific ligands with glial tumors may also make it possible to design cytotoxic agents that could be used to treat specific brain tumors. Furthermore, if tumors are shown to have specific profiles of different receptor binding sites depending on their tissue of origin and degree of malignancy, it might be possible to diagnose tumors based on the results of noninvasive imaging.
